

<b>Notice of References Cited</b>		Application/Control No.	Applicant(s)/Patent Under Reexamination	
		10/551,405	BERZOFSKY ET AL.	
		Examiner	Art Unit	Page 1 of 1
		Jeffrey S. Parkin	1648	

#### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-6,133,418	10-2000	Bolognesi et al.	530/324
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

#### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

#### NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Sarobe, P., et al., 1998, Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement as secondary HLA-A2.1 binding positions, J. Clin. Invest. 102:1239-1248.
	V	Berzofsky, J. A., et al., 1999, Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections, Immunol. Rev. 170:151-172.
	W	Berzofsky, J. A., et al., Strategies for designing and optimizing new generation vaccines, Nat. Rev. Immunol. 1:209-219.
*	X	Herrer, E., et al., 1996, Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor, J. Infect. Dis. 173:476-479.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.